Hennion & Walsh Asset Management’s Amylyx Pharmaceuticals AMLX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $364K | Sell |
56,831
-26,405
| -32% | -$169K | 0.01% | 769 |
|
|
2025
Q1 | $295K | Sell |
83,236
-7,383
| -8% | -$26.1K | 0.01% | 765 |
|
|
2024
Q4 | $343K | Sell |
90,619
-23,915
| -21% | -$90.4K | 0.02% | 728 |
|
|
2024
Q3 | $371K | Sell |
114,534
-4,449
| -4% | -$14.4K | 0.02% | 691 |
|
|
2024
Q2 | $226K | Buy |
118,983
+6,116
| +5% | +$11.6K | 0.01% | 784 |
|
|
2024
Q1 | $321K | Buy |
112,867
+27,937
| +33% | +$79.3K | 0.02% | 671 |
|
|
2023
Q4 | $1.25M | Buy |
84,930
+35,364
| +71% | +$521K | 0.07% | 352 |
|
|
2023
Q3 | $908K | Buy |
49,566
+14,427
| +41% | +$264K | 0.06% | 382 |
|
|
2023
Q2 | $758K | Buy |
35,139
+14,718
| +72% | +$317K | 0.04% | 424 |
|
|
2023
Q1 | $599K | Buy |
20,421
+3,465
| +20% | +$102K | 0.04% | 470 |
|
|
2022
Q4 | $627K | Buy |
+16,956
| New | +$627K | 0.04% | 450 |
|